Navigation Links
Viral 'fitness' explains different resistance patterns to aids drugs

Some HIV medications lead to the development of drug-resistant HIV when patients take as few as two percent of their medications. For other medications, resistance occurs only when patients take most of their pills. These differences appear to be explained by the different levels of viral "fitness" of the drug-resistant HIV, say AIDS researchers in a new study.

The research, led by David Bangsberg, MD, MPH, an AIDS specialist at the University of California, San Francisco, is reported in the January 9 issue of the journal AIDS.

Viral "fitness" refers to the inherent ability of a virus to replicate and cause disease. Incomplete pill-taking by patients causes HIV to mutate and become resistant to the effects of the medications, while the medications that were consumed, in turn, cause the newly resistant virus to become less fit.

The type of medication also factors in. Differences in viral fitness of mutated resistant virus occur between different classes of antiretroviral drugs, said Bangsberg, who is an associate professor of medicine at UCSF and director of the UCSF Epidemiology and Prevention Interventions Center at San Francisco General Hospital Medical Center.

When patients succeed in completely suppressing HIV, which requires that patients take all or almost all of their medications as directed, resistant strains either do not occur or are suppressed, he added.

Explaining the study results, Bangsberg said, "A non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, can be taken one time by a pregnant woman to prevent mother-to-child transmission, and NNRTI-resistant HIV virus can develop. Yet patients taking unboosted protease inhibitors (PI) do not experience the peak risk of PI-resistant HIV developing unless they are taking most of their PIs but fall just short of full viral suppression."

The researchers found that NNRTI-resistant virus has an advantage over sensitive virus even at very low levels o
'"/>

Source:University of California - San Francisco


Page: 1 2

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
3. Viral protein influences key cell-signaling pathway
4. Viral protein helps infected T cells stick to uninfected cells
5. Viral genetic differences are possible key to HIV dementia
6. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
7. Viral marker of human migration suspect
8. Viral protein is an effective preventative against infection
9. Gene sequencing explains bioremediation bug
10. New book explains antibiotic resistance for a broad audience
11. UGA study explains peaks and troughs of dengue epidemics
Post Your Comments:
(Date:10/30/2014)... have developed a suite of technologies that can be ... has applications in everything from search and rescue to ... a platform for computer-mediated communication between humans and dogs ... dogs, behavioral signals and sending them clear and unambiguous ... professor of computer science at NC State and co-lead ...
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... lose their hair as a consequence of chemotherapy will ... the scalp cooling technology that prevents hair loss. , ... pioneered by global scalp cooling manufacturing company, Paxman Coolers, ... department of the University of Huddersfield. , The research ... has a background in the pharmacology of cancer treatment, ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... common form of brewer's yeast, University of Wisconsin-Madison researchers have ... to act as a master regulatory switch -- a control ... may contribute to serious neurological disorders. , The work, published ... shows how a mutation in a single gene can have ...
... to determine the sequence of nucleotide bases in the ... at UC San Diego and eight other universities and ... lower the cost to only $1,000 per human genome ... crucial to understanding and routinely treating hundreds of inherited ...
... have shown that some simple biodegradable liquids can stop ... could significantly impact medicine. , When the liquid, composed ... wounds, the peptides self-assemble into a nanoscale protective barrier ... the injury heals, the nontoxic gel is broken down ...
Cached Biology News:From a lowly yeast, researchers divine a clue to human disease 2Scientists win grants to develop $1,000 genome sequencing technology 2MIT material stops bleeding in seconds 2MIT material stops bleeding in seconds 3
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Ardelyx, ... biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic ... quarter 2014 financial results on Thursday, November 6, ... will host a live conference call and webcast ... results and provide a business update. ...
(Date:10/30/2014)... 30, 2014 On October 26th ... Showcase in Chicago, leading applied stem cell research ... Wade McKenna presented talks on New Techniques for ... Applications For Stem Cells. , Dr. Riordan focused ... the properties of AlphaGEMS that include: wound healing; ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... 2014 Avure Technologies celebrates a year of ... member of its fleet of high volume High Pressure Processing ... as we return to PackExpo this year, which is where ... Vegas,” said Jeff Williams, CEO at Avure. “Sales of the ... to be meeting the challenges of market demand for higher ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... (Nasdaq: PRXL ) will release Third Quarter Fiscal ... the close of the stock,market. The announcement will be ... the PR Newswire website at http://www.prnewswire.com ., ... webcast at 10:00 a.m. EDT,on Thursday, April 24, 2008 ...
... N.C., March 26 Campbell Alliance, the leading,management ... announced today that George Schmidt, Vice President,in the ... the EyeForPharma,Sales Force Effectiveness (SFE) conference. The event ... the Centre Convencions Internacional in Barcelona, Spain., ...
... March 26 /Xinhua-PRNewswire-FirstCall/,-- Kiwa Bio-Tech Products Group Corporation ... year ended December 31, 2007 were,$9,129,779 an increase ... sales from continuing operations were $9,129,779 and $2,506,715 ... 2006, respectively,representing an increase of $6,623,064 or 264.2%. ...
Cached Biology Technology:PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 2Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 2Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 3Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 4Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 5Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 6Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million 7